NO-Cbl, a vitamin B12-based nitric oxide donor, crossed the blood-brain barrier in rat glioblastoma models and accumulated preferentially in tumor tissue, giving researchers an early potential route around a major treatment obstacle.
At least 24 hours after dosing, nitrate levels stayed elevated in tumor tissue while falling faster in normal organs, suggesting sustained activity and selective retention inside glioblastoma.
U87 and D54 glioblastoma cell tests showed NO-Cbl worked synergistically with temozolomide and TRAIL, suppressing tumor-cell growth more strongly than either treatment alone across multiple dose ranges.
Glioblastoma patients typically survive less than 15 months even with surgery, radiation and chemotherapy, and the authors said the pilot findings still need orthotopic validation, dose optimization and longer-term mechanistic study before clinical use.
Many brain cancer drugs fail in human trials. What makes this new B12 compound different from past promises?
This B12 'Trojan horse' kills brain cancer in lab studies. When could this breakthrough finally reach human patients?
NO-Cbl for Glioblastoma: Preclinical Promise, Mechanistic Insights, and Future Clinical Prospects
Overview
Glioblastoma is a fast-growing and hard-to-treat brain tumor, with current treatments focused on easing symptoms rather than curing the disease. Because survival rates remain low, researchers are searching for new solutions. Nitrosylcobalamin (NO-Cbl), a synthetic form of Vitamin B12, has recently emerged as a promising therapy. NO-Cbl can specifically target glioblastoma cells and trigger their death by activating caspase-8 and blocking survival pathways. This multi-pronged action may help overcome drug resistance, offering hope for patients whose tumors no longer respond to standard treatments. While still in preclinical stages, NO-Cbl represents a significant step forward in glioblastoma research.